Lars Melholt Rasmussen

Professor

Odense Universitetshospital
Country flagDenmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Lars Melholt Rasmussen holds a position at Odense Universitetshospital in Denmark. His research areas encompass cardiovascular screening, abdominal aortic aneurysms, and biomarker discovery through mass spectrometry-based proteomics. Recent articles include studies on cardiovascular outcomes in men and the mutational landscape of atherosclerotic plaques, among others. He is actively involved in advancing knowledge related to cardiovascular health and disease.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Acute myocardial infarction (AMI) is a major cause of mortality and morbidity worldwide, yet biomarkers for AMI in the short- or medium-term are lacking. We apply the discordant twin pair design, reducing genetic and environmental confounding, by linking nationwide registry data on AMI diagnoses to a survey of 12,349 twins, thereby identifying 39 twin pairs (48–79 years) discordant for their first-ever AMI within three years after blood sampling. Mass spectrometry of blood plasma identified 715 proteins. Among 363 proteins with a call rate > 50%, imputation and stratified Cox regression analysis revealed seven significant proteins (FDR < 0.05): FGD6, MCAM, and PIK3CB reflected an increased level in AMI twins relative to their non-AMI co-twins (HR > 1), while LBP, IGHV3-15, C1RL, and APOC4 reflected a decreased level in AMI twins relative to their non-AMI co-twins (HR < 1). Additional 50 proteins were nominally significant (p < 0.05), and bioinformatics analyses of all 57 proteins revealed biology within hemostasis, coagulation cascades, the immune system, and the extracellular matrix. A protein–protein-interaction network revealed Fibronectin 1 as a central hub. Finally, technical validation confirmed MCAM, LBP, C1RL, and APOC3. We put forward novel biomarkers for incident AMI, a part of the proteome field where markers are surprisingly rare and where additional studies are highly needed.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (19)

Axel C.P. Diederichsen

Odense University Hospital

DENMARK
View details

Lars Frost

Aarhus University

DENMARK
View details

Afsaneh Mohammadnejad

Assistant Professor

University of Southern Denmark

DENMARK
View details

Martin Jakob Larsen

Associate Professor

University of Southern Denmark

DENMARK
View details

Joshua Spin

Clinical Assistant Professor

Stanford University School of Medicine

UNITED STATES
View details

Rikke Hjortebjerg

University of Southern Denmark

DENMARK
View details

Ljubica Matic

Karolinska University Hospital

SWEDEN
View details

Ditte Hansen

Associate professor

University of Copenhagen

DENMARK
View details

Peter Højrup

University of Southern Denmark

DENMARK
View details

Oke Gerke

Professor in Clinical Biostatistics in Diagnostic Research

University of Southern Denmark

DENMARK
View details

Pernille J. Vinholt

Odense University Hospital

DENMARK
View details

Hans‐Christian Beck

-

DENMARK
View details

Jane Stubbe

aoosicate professor

University of Southern Denmark

DENMARK
View details

Jesper Hallas

Professor

University of Southern Denmark

DENMARK
View details

Jonas Heilskov Graversen

University of Southern Denmark

DENMARK
View details

Jonas Mengel-From

University of Southern Denmark

DENMARK
View details

Jes S. Lindholt

-

DENMARK
View details

Mette Soerensen

University of Southern Denmark

DENMARK
View details

Rikke Søgaard

Professor

University of Southern Denmark

DENMARK
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.